Targeted RNA-sequencing (RNA-Seq) is a highly accurate method for selecting and sequencing specific transcripts of interest. It offers both quantitative and qualitative information. Targeted RNA-Seq can be achieved via either enrichment or amplicon-based approaches, both of which enable gene expression analysis in a focused set of genes of interest. Enrichment assays also provide the ability to detect both known and novel gene fusion partners in many sample types, including formalin-fixed paraffin-embedded (FFPE) tissue.
RNA enrichment provides quantitative expression information as well as the detection of small variants and gene fusions. RNA enrichment offers the following features:
RNA expression panels can be designed to focus on RNA sequences of interest, or custom content can be added to fully optimized and experimentally validated panels.
Researchers are using the TruSight RNA Pan-Cancer Panel to understand the role of fusion genes in pediatric leukemia.Read Interview
Our RNA-Seq library prep solutions for targeted RNA sequencing include exceptionally fast, tagmentation-based workflows for deep insights into many transcripts of interest, including the RNA exome.Learn More
Dr. Frank Middleton from SUNY Upstate Medical University (UMU) developed a focused gene panel to screen for expression alterations caused by a newly discovered CNV in schizophrenia. See why Dr. Middleton used targeted RNA-Seq rather than PCR or arrays to analyze several hundred genes associated with schizophrenia, bipolar disorder, and autism.Read Interview
Illumina sequencing by synthesis (SBS) chemistry is the most widely adopted NGS technology, generating approximately 90% of global sequencing data.*
We offer integrated targeted RNA-Seq workflows that simplify the entire process, from library preparation to data analysis and biological interpretation.
Monitor gene expression and transcriptome changes with targeted RNA-Seq to better understand which variants are expressed and which may affect tumorigenesis and progression. Learn more about RNA-Seq in cancer research.
Explore genomic sequencing solutions for all phases of the drug development pipeline. Characterize gene expression profiles from a custom panel with a few defined targets to the whole transcriptome. Learn more about NGS in drug development.
Genomic technologies can help reveal the mechanisms behind complex neurological diseases such as Alzheimer’s and Parkinson's disease. Learn more about neurogenomics.
See how NGS enables research into autoimmune disease mechanisms, the immune repertoire, and the functional consequences of immune-related genetic variation. Learn more about immunogenomics.
Enter your email address.
*Data calculations on file. Illumina, Inc., 2015